Group 1 - UBS Group AG increased its stake in China National Nuclear Power Co., Ltd. (01763.HK) by purchasing 88,400 shares at an average price of HKD 20.8565 per share, totaling approximately HKD 1.8437 million [1] - Following this transaction, UBS Group AG's total shareholding rose to 4,004,922 shares, which represents an increase in ownership from 4.90% to 5.01% [1][2]

香港联交所最新资料显示，11月6日，瑞银增持中国同辐(01763)8.84万股，每股作价20.8565港元，总金 额约为184.37万港元。增持后最新持股数目约为400.49万股，最新持股比例为5.01%。 ...

智通财经APP获悉，香港联交所最新资料显示，11月6日，瑞银增持中国同辐(01763)8.84万股，每股作 价20.8565港元，总金额约为184.37万港元。增持后最新持股数目约为400.49万股，最新持股比例为 5.01%。 ...

每经AI快讯，中国同辐(01763.HK)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港 元，成交额1302.97万港元。 ...

Core Viewpoint - China Tongru (01763) has seen its stock price increase by over 130% this year, with a recent rise of 7.94% to HKD 24.48, driven by significant developments in the nuclear medicine sector [1] Group 1: Company Developments - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - China Tongru has launched carbon isotope products, marking a breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has officially initiated the construction of the second phase of its stable isotope base project, positioning itself as a leader in the complete industrial chain of breath test products [1] Group 2: Industry Insights - The approval of Pluvicto is anticipated to further ignite interest in the domestic nuclear medicine sector, with diagnostic nuclear drugs expected to see increased demand alongside therapeutic drugs [1] - Analysts suggest focusing on companies like China Tongru that are leading in the development of new isotopes and new targets within the nuclear medicine space [1]

Group 1 - China Tongru (01763) has seen its stock price increase by over 130% year-to-date, with a recent rise of 7.94% to HKD 24.48, and a trading volume of HKD 13.03 million [1] - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - Ping An Securities highlighted that the approval of Pluvicto may further ignite interest in the domestic nuclear medicine sector, suggesting to pay attention to companies like China Tongru that are leading in new isotopes and targets [1] Group 2 - On October 31, China Tongru announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has become a leading enterprise that fully masters the entire industry chain of breath test products and has officially initiated the construction of the second phase of its stable isotope base project [1]

Core Insights - As of November 10, a total of 108 stocks reached their 52-week highs, with notable performers including Taijin Holdings (08321), OKURA HOLDINGS (01655), and Hejia Holdings (00704) achieving high rates of 125.00%, 84.90%, and 53.57% respectively [1] Summary by Category 52-Week Highs - Taijin Holdings (08321) closed at 0.620 with a peak price of 0.900, marking a 125.00% increase - OKURA HOLDINGS (01655) reached a closing price of 0.280 and a high of 0.355, reflecting an 84.90% rise - Hejia Holdings (00704) had a closing price of 0.345 and a peak of 0.430, showing a 53.57% increase - Other notable stocks include Sanhe Chemical (00301) with a 41.67% increase and Aide New Energy (02623) with a 36.25% rise [1] 52-Week Lows - Wangshan Wangshui-B (02630) recorded a closing price of 52.850 and a low of 51.000, resulting in a -21.84% decrease - Eight Horses Tea (06980) had a closing price of 52.850 and a low of 51.100, reflecting a -10.98% decline - New Enjoy Times (08519) reached a low of 0.270, marking a -10.00% drop - Other significant declines include Jiujiang Bank (06190) at -8.99% and Kun Group (00924) at -6.98% [3][4]

Core Viewpoint - China Tongru (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the title of "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [13C/14C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the niche field of urea [13C] and [14C] breath diagnostics [1] - The urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers in China and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Dongfang (01763) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Pharmaceutical Industry Single Champion" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - The company focuses on the application of medical isotopes in the niche market of Urea [13C] and [14C] breath diagnostics [1] - The Urea [13C] and [14C] breath test products are used for detecting Helicobacter pylori [1] - The products cover over 20,000 end customers domestically and are sold to 90 countries and regions [1] - The market share has consistently ranked among the top in the industry for several years [1]

Core Viewpoint - China Tongru (01763.HK) announced that its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has successfully been selected as a national-level manufacturing enterprise and awarded the "Single Champion in the Pharmaceutical Industry" for its core product, the "Urea [C/C] Breath Test Kit" [1] Company Summary - China Tongru focuses on the application of medical isotopes in the urea [C] and [C] breath diagnostic niche, producing products used for detecting Helicobacter pylori [1] - The company's urea [C] and [C] breath test products cover over 20,000 end customers in China and are sold to 90 countries and regions, maintaining a leading market share in the industry for several consecutive years [1] Industry Summary - The company aims to further strengthen its position in technological innovation, continuously delve into breath diagnostics and related fields, and develop more advanced products and solutions to meet clinical needs, contributing to the health defense of the population [1]